NKCx Histopathological outcome* within 12 months after cervix cytology in 2018 |
Country Total |
Benign | CIN1 | CIN2 | CIN3 | AIS | Cancer | Other | PAD missing | Total | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytology | Count | Pct | Count | Pct | Count | Pct | Count | Pct | Antal | Andel | Count | Pct | Count | Pct | Count | Pct | Count | Pct |
Benign sample | 1873 | 0.6% | 393 | 0.1% | 11 | 0.0% | 150 | 0.0% | 6 | 0.0% | 11 | 0.0% | 86 | 0.0% | 317845 | 99.2% | 320375 | 100.0% |
ASCUS | 2503 | 15.6% | 2651 | 16.6% | 35 | 0.2% | 1517 | 9.5% | 28 | 0.2% | 22 | 0.1% | 254 | 1.6% | 8992 | 56.2% | 16002 | 100.0% |
CIN1 | 1540 | 17.8% | 2359 | 27.2% | 61 | 0.7% | 1534 | 17.7% | 19 | 0.2% | 13 | 0.1% | 169 | 1.9% | 2972 | 34.3% | 8667 | 100.0% |
Atypical glandular cells/AGC | 116 | 29.8% | 84 | 21.6% | 1 | 0.3% | 85 | 21.9% | 39 | 10.0% | 31 | 8.0% | 7 | 1.8% | 26 | 6.7% | 389 | 100.0% |
Unclear atypia | 72 | 34.1% | 34 | 16.1% | 2 | 0.9% | 59 | 28.0% | 6 | 2.8% | 6 | 2.8% | 11 | 5.2% | 21 | 10.0% | 211 | 100.0% |
ASC-H | 156 | 11.6% | 243 | 18.1% | 13 | 1.0% | 811 | 60.4% | 19 | 1.4% | 22 | 1.6% | 23 | 1.7% | 56 | 4.2% | 1343 | 100.0% |
CIN2 | 8 | 9.4% | 12 | 14.1% | 12 | 14.1% | 43 | 50.6% | . | . | 1 | 1.2% | 1 | 1.2% | 8 | 9.4% | 85 | 100.0% |
CIN3 | 198 | 5.9% | 309 | 9.2% | 26 | 0.8% | 2530 | 75.7% | 68 | 2.0% | 99 | 3.0% | 24 | 0.7% | 87 | 2.6% | 3341 | 100.0% |
Adenocarcinoma | 4 | 4.2% | 6 | 6.3% | . | . | 17 | 17.7% | 38 | 39.6% | 26 | 27.1% | 2 | 2.1% | 3 | 3.1% | 96 | 100.0% |
Malignant tumor with unclear origin | . | . | . | . | . | . | 1 | 33.3% | . | . | . | . | . | . | 2 | 66.7% | 3 | 100.0% |
Squamous cell cancer | 1 | 2.0% | 1 | 2.0% | . | . | 28 | 57.1% | . | . | 14 | 28.6% | . | . | 5 | 10.2% | 49 | 100.0% |
Total | 6471 | 1.8% | 6092 | 1.7% | 161 | 0.0% | 6775 | 1.9% | 223 | 0.1% | 245 | 0.1% | 577 | 0.2% | 330017 | 94.1% | 350561 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (CIN1) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80001, M80009, M80413, M80703, M81401, M81403, M81409, M83803, M84613, M85603 |